Having trouble viewing this email? View in your browser.

12 November 2019

Dear colleagues,

Please find below the latest edition of ESCMID Weekly News.

With kind regards,
ESCMID Executive Office.


ECCMID 2020 Abstract Submission – Submit your research!

Abstracts are being welcomed for inclusion at ECCMID 2020 in Paris! Visit the abstract website to view the regulations for submission and to submit your work to the world’s premier meeting in the field of clinical microbiology and infectious diseases.
Act now, submissions close on 27 November 2019!

› Read more

ESCMID Postgraduate Technical Workshop in Vienna –
Grants available!

Don’t miss the ESCMID Postgraduate Technical Workshop "Technical hospital hygiene – Tricks of the trade" to be held in Vienna from 6 – 8 February 2020.

View the programme and other details online here.

Attendance grant applications are being accepted until 30 November 2019, visit the ESCMID courses website to register for this and other great ESCMID Courses and Workshops.

› Read more

ISF/ESCMID Sepsis Award – Submit your Abstract today!

The ISF/ESCMID Sepsis Award 2020 is to recognize an outstanding abstract on a sepsis-related topic submitted to the 30th ECCMID in 2020.

By submitting an abstract in the sepsis category, you will automatically be entered into the running for the award, which gives the recipient a USD 500 award, as well as the opportunity to present their work on the ECCMID stage.

› Read more

Join us at ECCMID 2020 to experience the Symposium “Bacteriophages in current clinical practice” co-organized by the Trainee Association of ESCMID (TAE) Speakers: Jean-Paul Pirnay, Rebekah Dedrick

Bacteriophages are viruses that are able to infect and kill bacteria. Bacteriophages have been used in clinical practice for over 90 years, mostly in former Soviet Union countries and Central Europe. Bacteriophages could be used to treat infections caused by bacteria that are resistant to antibiotics. However, the evidence for the clinical use of bacteriophages is still mostly based on clinical experience rather than randomised studies. Many trials that study the effectiveness of bacteriophages are still ongoing and the debate whether bacteriophages are the solution to antibiotic resistance continues.

Visit ECCMID Live to discover more about our scientific programme and register now to take advantage of early registration discounts!

› Read more

New deadline for submission of proposals for ESCMID guidelines projects

Due to several requests received from ESCMID members, the deadline of the first ESCMID call for clinical practice guidelines 2019 has been postponed until Friday November 15th.

The objective of this call is to invite interested parties to propose to undertake the development of full clinical practice guidelines (following ESCMID guidance manual rules) in one of the priority topics, as listed above. 
The selected topics are:

1) Antimicrobial stewardship;

2) Diagnosis and management of influenza;

3) Surgical prophylaxis and infection control means, in patients colonised by MDR pathogens before surgery;

4) Diagnostic and treatment of non-hospitalized Community Acquired Pneumonia.

For more information, please visit our website

› Read more

Deadline extended - European Commission expert panels on medical devices and in vitro diagnostic devices

The European Commission has extended the deadline for the call for expressions of interest to appoint experts to scientific panels. The selected experts will need to provide consistent scientific, technical and/or clinical advice concerning the implementation of Regulation (EU) 2017/745 on medical devices.

› Read more

CMI Highlight: BCG strains with defined resistance mutations: a new tool for TB lab quality control

S. N. Danchuk et al, generated antibiotic resistant mycobacterial strains of attenuated virulence (M. bovis BCG) to provide safe QC reagents for the detection of drug-resistant Mycobacterium tuberculosis.

Laboratory quality control (QC) is essential to assess the reliability of tuberculosis diagnostic testing. While phenotypic drug susceptibility testing (DST) is generally done in reference laboratories, molecular testing can also be done in hospital labs, clinics and remote polyfunctional labs. These latter settings typically lack the capacity to safely propagate viable MDR strains of M. tuberculosis, as positive controls for these tests. As a result, outside of specialized TB labs, molecular testing is done without mycobacterial control strains.

The authors developed seven mono-resistant BCG strains by introducing resistance-conferring mutations into wildtype BCG strains. Mutations were confirmed by dideoxynucleotide sequencing. Phenotypic resistance was quantified by microbroth dilution to determine the minimal inhibitory concentration (MIC) 90. The capacity of two commercial tests (GeneXpert TB/RIF and Genotype MTBDRplus) to detect resistance-conferring mutations was evaluated independently.

Given the link between M. tuberculosis mutations and resistance, the authors have engineered the live attenuated vaccine (M. bovis BCG) to create strains which each present one defined mutation. This BCG panel can be used for laboratory quality control (QC), especially in labs with no mycobacteriology capacity, and could serve in proficiency testing for laboratories that diagnose MDR-TB by genetic and/or phenotypic methodologies.

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Phone +41 61 5080 173
Visit us on LinkedIn Visit us on YouTube
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.